Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 20

1.

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ; VIGOR Study Group..

N Engl J Med. 2000 Nov 23;343(21):1520-8, 2 p following 1528.

2.

Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers.

Van Hecken A, Schwartz JI, Depré M, De Lepeleire I, Dallob A, Tanaka W, Wynants K, Buntinx A, Arnout J, Wong PH, Ebel DL, Gertz BJ, De Schepper PJ.

J Clin Pharmacol. 2000 Oct;40(10):1109-20.

PMID:
11028250
3.

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.

Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ; Alzheimer's Disease Cooperative Study..

JAMA. 2003 Jun 4;289(21):2819-26.

PMID:
12783912
4.
5.

Celecoxib, but not rofecoxib or naproxen, attenuates cardiac hypertrophy and fibrosis induced in vitro by angiotensin and aldosterone.

Wang BH, Bertucci MC, Ma JY, Adrahtas A, Cheung RY, Krum H.

Clin Exp Pharmacol Physiol. 2010 Sep;37(9):912-8. doi: 10.1111/j.1440-1681.2010.05405.x. Epub 2010 May 24.

PMID:
20497423
6.

Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial.

Lisse JR, Perlman M, Johansson G, Shoemaker JR, Schechtman J, Skalky CS, Dixon ME, Polis AB, Mollen AJ, Geba GP; ADVANTAGE Study Group..

Ann Intern Med. 2003 Oct 7;139(7):539-46.

PMID:
14530224
7.

Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.

Schwartz JI, Vandormael K, Malice MP, Kalyani RN, Lasseter KC, Holmes GB, Gertz BJ, Gottesdiener KM, Laurenzi M, Redfern KJ, Brune K.

Clin Pharmacol Ther. 2002 Jul;72(1):50-61.

PMID:
12152004
8.
9.

Analgesic efficacy of the cyclooxygenase-inhibiting nitric oxide donor AZD3582 in postoperative dental pain: Comparison with naproxen and rofecoxib in two randomized, double-blind, placebo-controlled studies.

Michael Hill C, Sindet-Pederson S, Seymour RA, Hawkesford JE 2nd, Coulthard P, Lamey PJ, Gerry Cowan C, Wickens M, Jeppsson L, Dean AD, Svensson O.

Clin Ther. 2006 Sep;28(9):1279-95.

PMID:
17062301
10.

Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study.

Hawkey CJ, Laine L, Simon T, Quan H, Shingo S, Evans J; Rofecoxib Rheumatoid Arthritis Endoscopy Study Group..

Gut. 2003 Jun;52(6):820-6. Erratum in: Gut. 2003 Dec;52(12):1800.

11.

Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension.

Reiff A, Lovell DJ, Adelsberg JV, Kiss MH, Goodman S, Zavaler MF, Chen PY, Bolognese JA, Cavanaugh P Jr, Reicin AS, Giannini EH.

J Rheumatol. 2006 May;33(5):985-95. Epub 2006 Apr 1.

PMID:
16583464
12.

Lack of Pharmacokinetic Interaction between Esomeprazole and the Nonsteroidal Anti-Inflammatory Drugs Naproxen and Rofecoxib in Healthy Subjects.

Hassan-Alin M, Naesdal J, Nilsson-Pieschl C, Långström G, Andersson T.

Clin Drug Investig. 2005;25(11):731-40.

PMID:
17532719
13.
14.

A quantitative evaluation of the regulatory assessment of the benefits and risks of rofecoxib relative to naproxen: an application of the incremental net-benefit framework.

Lynd LD, Marra CA, Najafzadeh M, Sadatsafavi M.

Pharmacoepidemiol Drug Saf. 2010 Nov;19(11):1172-80. doi: 10.1002/pds.1994.

PMID:
20602338
15.
16.

Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake.

Huledal G, Jonzon B, Malmenäs M, Hedman A, Andersson LI, Odlind B, Brater DC.

Clin Pharmacol Ther. 2005 May;77(5):437-50.

PMID:
15900289
17.

Comparison of low-dose rofecoxib versus 1000 mg naproxen in patients with osteoarthritis. Results of two randomized treatment trials of six weeks duration.

Myllykangas-Luosujärvi R, Lu HS, Chen SL, Choon D, Amante C, Chow CT, Pasero G, Genti G, Sarembock B, Zerbini CA, Vrijens F, Moan A, Rodgers DB, De Tora L, Laurenzi M; Naproxen 901 OF study group Naproxen 901 OC study group..

Scand J Rheumatol. 2002;31(6):337-44.

PMID:
12492248
18.

Upper gastrointestinal toxicity of rofecoxib and naproxen.

Gupta S.

N Engl J Med. 2001 May 3;344(18):1398; author reply 1398-9. No abstract available.

PMID:
11336057
19.

Upper gastrointestinal toxicity of rofecoxib and naproxen.

Delgado Fernández M, Zambrana García JL, Diez García F.

N Engl J Med. 2001 May 3;344(18):1398; author reply 1398-9. No abstract available.

20.

A comparative study of the effect of rofecoxib (a COX 2 inhibitor) and naproxen sodium on analgesic requirements after abdominal hysterectomy.

Celik JB, Tuncer S, Reisli R, Sarkilar G, Celik C, Akyürek C.

Arch Gynecol Obstet. 2003 Oct;268(4):297-300. Epub 2002 Sep 26.

PMID:
14504873

Supplemental Content

Support Center